Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19.

IF 1.3 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren Pub Date : 2025-02-01 Epub Date: 2024-07-22 DOI:10.1055/a-2293-8132

{"title":"Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19.","authors":"","doi":"10.1055/a-2293-8132","DOIUrl":null,"url":null,"abstract":"Purpose: The prevalent coronavirus disease 2019 (COVID-19) pandemic has spread throughout the world and is considered a serious threat to global health. The prognostic role of thoracic lymphadenopathy in COVID-19 is unclear. The aim of the present meta-analysis was to analyze the prognostic role of thoracic lymphadenopathy for the prediction of 30-day mortality in patients with COVID-19.Materials and methods: The MEDLINE library, Cochrane, and SCOPUS databases were screened for associations between CT-defined features and mortality in COVID-19 patients up to June 2021. In total, 21 studies were included in the present analysis. The quality of the included studies was assessed by the Newcastle-Ottawa Scale. The meta-analysis was performed using RevMan 5.3. Heterogeneity was calculated by means of the inconsistency index I2. DerSimonian and Laird random-effect models with inverse variance weights were performed without any further correction.Results: The included studies comprised 4621 patients. The prevalence of thoracic lymphadenopathy varied between 1 % and 73.4 %. The pooled prevalence was 16.7 %, 95 % CI = (15.6 %; 17.8 %). The hospital mortality was higher in patients with thoracic lymphadenopathy (34.7 %) than in patients without (20.0 %). The pooled odds ratio for the influence of thoracic lymphadenopathy on mortality was 2.13 (95 % CI = [1.80-2.52], p < 0.001).Conclusion: The prevalence of thoracic lymphadenopathy in COVID-19 is 16.7 %. The presence of thoracic lymphadenopathy is associated with an approximately twofold increase in the risk for hospital mortality in COVID-19.Key points: · The prevalence of lymphadenopathy in COVID-19 is 16.7 %.. · Patients with lymphadenopathy in COVID-19 have a higher risk of mortality during hospitalization.. · Lymphadenopathy nearly doubles mortality and plays an important prognostic role..Citation format: · Bucher AM, Sieren M, Meinel F et al. Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19. Rofo 2025; 197: 163 - 171.","PeriodicalId":21490,"journal":{"name":"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren","volume":" ","pages":"163-171"},"PeriodicalIF":1.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2293-8132","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The prevalent coronavirus disease 2019 (COVID-19) pandemic has spread throughout the world and is considered a serious threat to global health. The prognostic role of thoracic lymphadenopathy in COVID-19 is unclear. The aim of the present meta-analysis was to analyze the prognostic role of thoracic lymphadenopathy for the prediction of 30-day mortality in patients with COVID-19.

Materials and methods: The MEDLINE library, Cochrane, and SCOPUS databases were screened for associations between CT-defined features and mortality in COVID-19 patients up to June 2021. In total, 21 studies were included in the present analysis. The quality of the included studies was assessed by the Newcastle-Ottawa Scale. The meta-analysis was performed using RevMan 5.3. Heterogeneity was calculated by means of the inconsistency index I2. DerSimonian and Laird random-effect models with inverse variance weights were performed without any further correction.

Results: The included studies comprised 4621 patients. The prevalence of thoracic lymphadenopathy varied between 1 % and 73.4 %. The pooled prevalence was 16.7 %, 95 % CI = (15.6 %; 17.8 %). The hospital mortality was higher in patients with thoracic lymphadenopathy (34.7 %) than in patients without (20.0 %). The pooled odds ratio for the influence of thoracic lymphadenopathy on mortality was 2.13 (95 % CI = [1.80-2.52], p < 0.001).

Conclusion: The prevalence of thoracic lymphadenopathy in COVID-19 is 16.7 %. The presence of thoracic lymphadenopathy is associated with an approximately twofold increase in the risk for hospital mortality in COVID-19.

Key points: · The prevalence of lymphadenopathy in COVID-19 is 16.7 %.. · Patients with lymphadenopathy in COVID-19 have a higher risk of mortality during hospitalization.. · Lymphadenopathy nearly doubles mortality and plays an important prognostic role..

Citation format: · Bucher AM, Sieren M, Meinel F et al. Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19. Rofo 2025; 197: 163 - 171.

查看原文本刊更多论文

胸部淋巴结病在 Covid-19 中的发病率和预后作用。

目的：流行性冠状病毒病 2019（COVID-19）大流行已蔓延至世界各地，被认为是对全球健康的严重威胁。胸腔淋巴结病在 COVID-19 中的预后作用尚不明确。本荟萃分析旨在分析胸部淋巴结病在预测 COVID-19 患者 30 天死亡率方面的预后作用：筛选了MEDLINE图书馆、Cochrane和SCOPUS数据库中截至2021年6月COVID-19患者的CT定义特征与死亡率之间的关系。本分析共纳入 21 项研究。纳入研究的质量采用纽卡斯尔-渥太华量表进行评估。荟萃分析使用 RevMan 5.3 进行。异质性通过不一致指数 I2 进行计算。使用反方差权重的 DerSimonian 和 Laird 随机效应模型进行分析，无需进一步校正：结果：纳入的研究包括 4621 名患者。胸部淋巴结病的发病率介于 1% 和 73.4% 之间。汇总患病率为 16.7%，95% CI = (15.6%; 17.8%)。胸腔淋巴结病患者的住院死亡率（34.7%）高于无胸腔淋巴结病患者（20.0%）。胸腔淋巴结病对死亡率影响的合计几率比为 2.13（95 % CI = [1.80-2.52]，p 结论：胸腔淋巴结病的发病率与死亡率之间存在显著相关性：在 COVID-19 中，胸部淋巴结病的发病率为 16.7%。在 COVID-19 中，胸腔淋巴结病的存在与住院死亡率风险增加约两倍有关：- COVID-19中淋巴结病的发病率为16.7%。- COVID-19中患有淋巴腺病的患者在住院期间的死亡风险较高。- 淋巴结病几乎使死亡率增加一倍，对预后起着重要作用：- Bucher AM, Sieren M, Meinel F et al.Covid-19胸腔淋巴结病的患病率和预后作用。Fortschr Röntgenstr 2024; DOI: 10.1055/a-2293-8132.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren 医学-核医学

CiteScore

1.20

自引率

5.60%

发文量

340

期刊介绍： Die RöFo veröffentlicht Originalarbeiten, Übersichtsartikel und Fallberichte aus dem Bereich der Radiologie und den weiteren bildgebenden Verfahren in der Medizin. Es dürfen nur Arbeiten eingereicht werden, die noch nicht veröffentlicht sind und die auch nicht gleichzeitig einer anderen Zeitschrift zur Veröffentlichung angeboten wurden. Alle eingereichten Beiträge unterliegen einer sorgfältigen fachlichen Begutachtung. Gegründet 1896 – nur knapp 1 Jahr nach der Entdeckung der Röntgenstrahlen durch C.W. Röntgen – blickt die RöFo auf über 100 Jahre Erfahrung als wichtigstes Publikationsmedium in der deutschsprachigen Radiologie zurück. Sie ist damit die älteste radiologische Fachzeitschrift und schafft es erfolgreich, lange Kontinuität mit dem Anspruch an wissenschaftliches Publizieren auf internationalem Niveau zu verbinden. Durch ihren zentralen Platz im Verlagsprogramm stellte die RöFo die Basis für das heute umfassende und erfolgreiche Radiologie-Medienangebot im Georg Thieme Verlag. Besonders eng verbunden ist die RöFo mit der Geschichte der Röntgengesellschaften in Deutschland und Österreich. Sie ist offizielles Organ von DRG und ÖRG und die Mitglieder der Fachgesellschaften erhalten die Zeitschrift im Rahmen ihrer Mitgliedschaft. Mit ihrem wissenschaftlichen Kernteil und dem eigenen Mitteilungsteil der Fachgesellschaften bietet die RöFo Monat für Monat ein Forum für den Austausch von Inhalten und Botschaften der radiologischen Community im deutschsprachigen Raum.